Skip to main content
Guidance

Sickle cell and thalassaemia screening pathway requirements

An overview of the sickle cell and thalassaemia (SCT) screening end-to-end pathway.

Updates to this page

From:
NHS England
Published:
21 June 2021
Last updated:
19 December 2024
Show all updates

  1. Removed 'specification' from the title of the HTML document.

  2. Removed 'specification' from the title. Changed lead organisation from Office for Health Improvement and Disparities to NHS England. Removed DHSC email address.

  3. First published.

Applies to England

Documents

Sickle cell and thalassaemia screening pathway requirements

HTML

Sickle cell and thalassaemia screening: learning from incidents

HTML

Details

This document provides an overview of SCT screening by describing what should happen at each stage of the end-to-end pathway.

In this publication, we use the terms ‘woman’ and ‘women’ to refer to anyone able to become pregnant, including trans men. Trans men who are pregnant should be offered the same antenatal and newborn screening tests as other pregnant individuals.

Sign up for emails or print this page

Related content